Rochester, MN, USA - Resoundant, Inc. Chief Operating Office, Troy Ziegler, issued the following statement on Congress' passage of the 21st Century Cures Act. "We are thrilled to see the passage of this important piece of legislation, which will give a much needed boost in funding to the National Institutes of Health (NIH), as well as streamline the process for bringing new medical innovations to market. "Here are Resoundant, we maintain an active and productive research program on new applications for MRE. This research program was largely born out of NIH support dating back over two decades. So we know first hand how important publicly funded research is to the pipeline for innovative new technologies.
"Among other provisions, we are also very pleased to see the addition of new patient experience data to drug and device approval process. Adding a patient-centered approach to the regulatory process will enrich and inform the process tremendously.
"We would like to thank the members of Congress, as well as Vice President Joe Biden, for their work on the Cures Act."